ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#12

August 2026

Cychlorphine Is in 8 States and Leading the Post-Nitazene Wave. No Standard Immunoassay Will Catch It.

When China placed nitazenes under generic schedule controls in July 2025, the forensic community expected displacement into structural analogs. Cychlorphine (N-propionitrile chlorphine) is the compound that has emerged most clearly in the data. The Center for Forensic Science Research and Education (CFSRE) has confirmed 25 fatal overdose specimens with cychlorphine present. NMS Labs has logged over 100 identifications across 8 states. Mid-Atlantic exposure is emerging. The DEA named cychlorphine alongside medetomidine, nitazenes, and xylazine in its May 2026 public safety advisory.

Cychlorphine is a synthetic opioid. It is not an isotonitazene and does not share the nitazene scaffold. Standard fentanyl immunoassays, standard opiate immunoassays, and standard opioid confirmation panels built without an explicit cychlorphine or N-propionitrile chlorphine target will not detect it. Detection requires expanded confirmatory mass spectrometry. Like most novel synthetic opioids appearing in the illicit supply, cychlorphine was found in combination with fentanyl in the available case reports, which means naloxone remains the appropriate initial reversal agent; the concern is co-exposure adding to CNS and respiratory depression in a patient who may not respond fully to standard reversal doses.

The supply pattern here is important context. Nitazenes showed up in the data before they showed up in clinical protocols; there was a lag between first forensic detection and the point where emergency departments, OTPs, and coroners had reliable detection. Cychlorphine is earlier in that arc. Programs that have not expanded their confirmatory panels beyond fentanyl and traditional opioids may already be missing it.

CFSRE public alert, January 2026.  ·  DEA Public Safety Advisory, May 12, 2026.  ·  NMS Labs surveillance data.

◷  Watch Date

DEA Scheduling: Effective Aug 5 (Earliest)

7-Hydroxymitragynine Is About to Become Schedule I. The Threshold Matters More Than the Headline.

DEA published notices of intent on July 6 to temporarily place 7-hydroxymitragynine (7-OH) in Schedule I at threshold concentrations: 0.05% for kratom plant material, and 0.05% or 1 mg per article for extracts, concentrates, edibles, and pressed pills. A companion notice covers mitragynine pseudoindoxyl, MGM-15, and MGM-16. The HHS request for information period closed July 31; the order can publish on or after August 5 and takes effect on publication for a two-year temporary period.

What stays legal: plain leaf kratom and products where 7-OH is present only at naturally occurring concentrations below 0.05%. What becomes Schedule I: concentrated extracts, tinctures, edibles, and pressed pills that exceed the threshold; these are the high-potency products that have been most actively marketed as opioid substitutes.

The clinical implication is immediate: patients at OTPs and CTCs who have been using concentrated 7-OH products as opioid substitutes or to manage withdrawal will lose retail access once the order publishes. Expect these patients to present for MOUD induction or to show up in withdrawal within weeks of the order's publication. For lab programs: standard immunoassay panels do not detect mitragynine or 7-OH; demand for LC-MS/MS kratom alkaloid confirmation panels will likely increase. Sources: Federal Register.

SYSTEMATIC REVIEW / NETWORK META-ANALYSIS 2026

Long-Acting Injectable Buprenorphine Outperforms Daily Transmucosal Formulations on Retention. The Trade-Off Is Flexibility.

A systematic review and network meta-analysis (PMID 41521864) comparing long-acting injectable (LAI) buprenorphine against transmucosal buprenorphine, methadone, and implants across randomized and observational studies through March 2025 offers the clearest current synthesis of where LAI fits in the MOUD toolkit. LAI formulations showed favorable retention compared to daily sublingual buprenorphine-naloxone across most included analyses, with a consistent signal toward reduced illicit opioid use during the observation period. The evidence base for methadone's effectiveness remains strong, particularly for patients with severe dependence and structural barriers to adherence.

The network structure of the analysis allows direct and indirect comparisons across formulations in a way that individual RCTs cannot, though the authors note heterogeneity across studies in how treatment retention and opioid use outcomes were defined. The practical question for clinicians is less about which formulation is globally superior and more about which formulation fits a specific patient's situation: adherence pattern, occupational constraints, insurance coverage, and preference for flexibility versus structure.

Systematic review and network meta-analysis through March 2025. PMID 41521864.

Also From ToxiPharm This Week

Tox Pearl #12  ·  Medetomidine Withdrawal Is Not Opioid Withdrawal: why COWS misses severity, 77.5% ICU in the Philadelphia series, and when to escalate to IV dexmedetomidine.